Preparation and use of metalloproteinase-activated car-t structure
By introducing TSAR regulatory elements into CAR-T cells, using matrix metalloproteinase in the tumor microenvironment for conditional activation, the toxic side effects caused by off-target effects in CAR-T cell therapy are solved, and the treatment safety and efficacy are improved.
Patent Information
- Application Number
- PCT/CN2024/096088
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-29
- Publication Date
- 2024-12-05
AI Technical Summary
There are toxic side effects caused by off-target effects in CAR-T cell therapy, resulting in normal tissue damage. Existing strategies such as the selection of low-affinity single-chain antibodies and logic-gated CAR molecules have limitations, making it difficult to effectively reduce toxic side effects and improve safety.
Design a conditionally activated chimeric antigen receptor (CAR) that contains TSAR regulatory elements, including serum albumin-binding peptides and matrix metalloproteinase cleavage sequences, and use highly expressed matrix metalloproteinases in the tumor microenvironment for conditional activation to reduce detargeting effect, improve safety.
Through the conditional activation of matrix metalloproteinase, CAR-T cells are effectively activated in the tumor environment, reducing attack on normal tissues, reducing toxic side effects, and improving treatment safety and efficacy.
Smart Images

Figure PCTCN2024096088-FTAPPB-I100001 
Figure PCTCN2024096088-FTAPPB-I100002 
Figure PCTCN2024096088-FTAPPB-I100003
Abstract
Description
Preparation and application of a metalloproteinase-activated CAR-T structure Technical Field
[0001] The present invention relates to the technical fields of genetic engineering and molecular immunology, and particularly to the preparation and application of a metalloproteinase-activated CAR-T structure. Background Art
[0002] Tumor cells can evade T cell recognition and attack due to loss / modulation of surface antigens and loss or reduced expression of major histocompatibility complex (MHC) class I molecules, leading to immune escape. Chimeric antigen receptor T cells, or CAR-T cells, are a novel cell therapy product that has been genetically engineered to specifically recognize and kill tumor cells. Their mediated antigen recognition is not restricted by MHC and has become one of the most promising treatments for malignant tumors. The classic CAR structure consists of a tumor-associated antigen-binding region, an extracellular hinge region, a transmembrane region, and an intracellular signaling region.
[0003] CAR-T cells targeting CD19 and CD22 have been widely used in the treatment of hematologic malignancies, including B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma, with remarkable efficacy. In recent years, a growing number of CAR-T cell products have been developed for the treatment of malignant solid tumors, some of which have entered clinical trials. Although CAR-T cell therapy has become one of the most promising biotherapeutic approaches, toxic side effects, such as off-target effects of the CAR molecule, cytokine release syndrome, and CAR-T-associated encephalopathy syndrome, remain unresolved. Therefore, while improving the efficacy of CAR-T, further enhancing the safety of CAR-T cell products is also crucial.
[0004] Currently, most CAR-T cells target tumor-associated antigens rather than tumor-specific antigens. This results in CAR-T cells inevitably killing normal tissue cells expressing the same target antigens (i.e., off-target effects) while killing tumor cells. This can cause damage or failure of normal tissues and organs, and in severe cases, can be life-threatening. There are currently two strategies to address off-target effects. One is to select single-chain antibodies with different affinities for the target antigen based on the differences in surface antigen expression between normal tissues and organs and malignant tumor cells. The other is to introduce "logic-gated" CAR molecules that simultaneously recognize two or more antigens or lack specific antigens to optimize CAR recognition of tumor cells. However, both strategies still have limitations.
[0005] Therefore, there is an urgent need in this field to develop a new strategy to address off-target effects and to develop an engineered immune cell product with lower toxic side effects and higher safety.
[0006] Summary of the Invention
[0007] The purpose of the present invention is to provide a conditionally activated chimeric antigen receptor (CAR) and engineered immune cells.
[0008] Another object of the present invention is to provide a preparation method and application of conditionally activated chimeric antigen receptor (CAR) and engineered immune cells.
[0009] Another object of the present invention is to provide an immunotherapy that is less likely to have off-target effects, has lower toxic side effects, and is safer.
[0010] In a first aspect of the present invention, a conditionally activated chimeric antigen receptor (CAR) is provided, wherein the conditionally activated chimeric antigen receptor comprises:
[0011] (i) an extracellular domain comprising a TSAR regulatory element and an antigen recognition domain;
[0012] (ii) a transmembrane domain linked to the extracellular domain; and
[0013] (iii) an intracellular domain connected to the transmembrane domain;
[0014] in:
[0015] The TSAR regulatory element includes: a serum albumin binding peptide and a matrix metalloproteinase cleavage sequence;
[0016] The antigen recognition domain targets tumor antigens.
[0017] In another preferred embodiment, the TSAR regulatory element has a nucleotide sequence selected from the group consisting of:
[0018] (a) a nucleotide sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 1 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0019] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO: 1.
[0020] In another preferred embodiment, the TSAR regulatory element has a nucleotide sequence as shown in SEQ ID NO: 1.
[0021] In another preferred embodiment, the TSAR regulatory element has an amino acid sequence selected from the group consisting of:
[0022] (a) an amino acid sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 2 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0023] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 2.
[0024] In another preferred embodiment, the TSAR regulatory element has the amino acid sequence shown in SEQ ID NO: 2.
[0025] In another preferred embodiment, the serum albumin binding peptide is a human serum albumin binding peptide.
[0026] In another preferred embodiment, the serum albumin binding peptide has a nucleotide sequence selected from the following group:
[0027] (a) a nucleotide sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 3 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0028] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO: 3.
[0029] In another preferred embodiment, the serum albumin binding peptide has a nucleotide sequence as shown in SEQ ID NO: 3.
[0030] In another preferred embodiment, the serum albumin binding peptide has an amino acid sequence selected from the group consisting of:
[0031] (a) an amino acid sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 4 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0032] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 4.
[0033] In another preferred embodiment, the serum albumin binding peptide has the amino acid sequence shown in SEQ ID NO:4.
[0034] In another preferred embodiment, the matrix metalloproteinase cleavage sequence is a human matrix metalloproteinase cleavage sequence.
[0035] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has a nucleotide sequence selected from the group consisting of:
[0036] (a) a nucleotide sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 5 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0037] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or substituting at least one nucleotide based on the sequence shown in SEQ ID NO: 5.
[0038] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has a nucleotide sequence as shown in SEQ ID NO:5.
[0039] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has an amino acid sequence selected from the group consisting of:
[0040] (a) an amino acid sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 6 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0041] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 6.
[0042] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has an amino acid sequence as shown in SEQ ID NO: 6.
[0043] In another preferred embodiment, the matrix metalloproteinase cleavage sequence is a site recognized and cleaved by matrix metalloproteinase (MMP).
[0044] In another preferred embodiment, the matrix metalloproteinase is selected from the following group: MMP1, MMP2, MMP3, MMP4, MMP5, MMP6, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, or a combination thereof.
[0045] In another preferred embodiment, the matrix metalloproteinase is selected from the group consisting of MMP1, MMP3, MMP10, MMP12, MMP13, or a combination thereof.
[0046] In another preferred embodiment, the matrix metalloproteinase is MMP1.
[0047] In another preferred embodiment, the conditionally activated chimeric antigen receptor has an amino acid sequence selected from the group consisting of:
[0048] (a) an amino acid sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 8 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0049] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 8.
[0050] In another preferred embodiment, the conditionally activated chimeric antigen receptor has an amino acid sequence as shown in SEQ ID NO:8.
[0051] In another preferred embodiment, the tumor antigens include but are not limited to the following group:
[0052] B7-H3, VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, C D123, CD171, CD276, B7H4, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3 HER-2, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD44V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothel in, NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRa, TCRp, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79b, Notch-1-4, or combinations thereof.
[0053] In another preferred embodiment, the tumor antigen is B7-H3.
[0054] In another preferred embodiment, the tumor includes but is not limited to the following group:
[0055] Esophageal malignancy, lung malignancy, stomach malignancy, skin malignancy, colorectal malignancy, liver malignancy, pancreatic malignancy, breast malignancy, ovarian malignancy, glioma, head and neck tumor, or a combination thereof.
[0056] In another preferred embodiment, the tumor is esophageal malignant tumor (esophageal cancer).
[0057] In another preferred embodiment, the tumor is gastric cancer.
[0058] In another preferred embodiment, the tumor is colorectal cancer.
[0059] In another preferred embodiment, the tumor is liver cancer.
[0060] In another preferred embodiment, the tumor is pancreatic cancer.
[0061] In another preferred embodiment, the tumor is melanoma.
[0062] In another preferred embodiment, the tumor is lung cancer.
[0063] In another preferred embodiment, the tumor is ovarian cancer.
[0064] In another preferred embodiment, the tumor is breast cancer.
[0065] In another preferred embodiment, the tumor is a glioma.
[0066] In another preferred embodiment, the tumor is thyroid cancer.
[0067] In another preferred embodiment, the tumor is bladder cancer, prostate cancer, testicular cancer, cervical cancer, endometrial cancer, or skin cancer.
[0068] In another preferred embodiment, the tumor includes diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, lung squamous cell carcinoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, uterine carcinosarcoma, or a combination thereof.
[0069] In another preferred embodiment, the conditionally activated chimeric antigen receptor has a structure shown in Formula I: SP-TSAR-Binder-H-TM-C-CD3ζ (I)
[0070] Where,
[0071] SP is none or signal peptide sequence;
[0072] TSAR is the TSAR regulatory element;
[0073] Binder is an antigen recognition domain that specifically binds to tumor antigens;
[0074] H is none or hinge region;
[0075] TM is the transmembrane domain;
[0076] C is the costimulatory signaling domain;
[0077] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type or mutant / modified forms thereof);
[0078] The "-" is a connecting peptide or peptide bond.
[0079] In another preferred embodiment, the SP is selected from the signal peptides of the following histones: CD8, GM-CSF, CD4, CD28, CD137, or mutants / modified forms thereof, or a combination thereof.
[0080] In another preferred embodiment, the Binder is a B7-H3 single-chain antibody (B7-H3 scFv).
[0081] In another preferred embodiment, the H is selected from the hinge region of the following histones: CD8, CD28, CD137, IgG, or a combination thereof.
[0082] In another preferred embodiment, the H is the CD8 hinge region.
[0083] In another preferred embodiment, the TM is selected from the transmembrane region of the following histones: CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, CD278, CD152, CD279, CD233, or mutants / modified forms thereof, or combinations thereof.
[0084] In another preferred embodiment, the TM is the CD8 transmembrane region.
[0085] In another preferred embodiment, the C is selected from the costimulatory signaling domains of the following histones: OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD-1, Dap10, LIGHT, NKG2C, B7-H3, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, OX40L, 2B4, TLR, or mutants / modified forms thereof, or combinations thereof.
[0086] In another preferred embodiment, the C is a CD137 (4-1BB) costimulatory signaling domain, a CD28 costimulatory signaling domain, or a combination thereof.
[0087] In the second aspect of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule encodes the conditionally activated chimeric antigen receptor according to the first aspect of the present invention.
[0088] In another preferred embodiment, the nucleic acid molecule has a nucleotide sequence selected from the group consisting of:
[0089] (a) a nucleotide sequence having 80% or greater homology to the sequence shown in SEQ ID NO: 7 (preferably at least 85%, 90%, 95%, 99% or 100% homology); or
[0090] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO: 7.
[0091] In another preferred embodiment, the nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO:7.
[0092] In the third aspect of the present invention, a vector is provided, wherein the vector contains the nucleic acid molecule according to the second aspect of the present invention.
[0093] In another preferred embodiment, the vector is selected from the group consisting of DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, or a combination thereof.
[0094] In another preferred embodiment, the vector is a lentiviral vector.
[0095] In another preferred embodiment, the vector is selected from the following group: pTomo lentiviral vector, plenti, pLVTH, pLJM1, pHCMV, pLBS.CAG, pHR, pLV, etc.
[0096] In another preferred embodiment, the vector further comprises a member selected from the group consisting of: a promoter, a transcription enhancing element WPRE, a long terminal repeat sequence LTR, and the like.
[0097] In the fourth aspect of the present invention, a host cell is provided, which contains the vector as described in the third aspect of the present invention, or an exogenous nucleic acid molecule as described in the second aspect of the present invention is integrated into its chromosome, or it expresses the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention.
[0098] In the fifth aspect of the present invention, an engineered immune cell is provided, which contains the vector described in the third aspect of the present invention, or an exogenous nucleic acid molecule as described in the second aspect of the present invention is integrated into its chromosome, or it expresses the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, and the engineered immune cell is a T cell, NK cell, NKT cell, or macrophage.
[0099] In another preferred embodiment, the engineered immune cells include autologous or allogeneic αβT cells, γδT cells, NKT cells, NK cells, or a combination thereof.
[0100] In another preferred embodiment, the engineered immune cells are CAR-T cells or CAR-NK cells.
[0101] In the sixth aspect of the present invention, a method for preparing the engineered immune cells as described in the fifth aspect of the present invention is provided, the method comprising the following steps: transducing the nucleic acid molecule as described in the second aspect of the present invention or the vector as described in the third aspect of the present invention into the immune cells, thereby obtaining the engineered immune cells.
[0102] In another preferred embodiment, the method further comprises the step of performing functional and effectiveness testing on the obtained engineered immune cells.
[0103] In a seventh aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0104] (Z1) the conditionally activated chimeric antigen receptor according to the first aspect of the present invention, the nucleic acid molecule according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention, the engineered immune cell according to the fifth aspect of the present invention, or a combination thereof; and
[0105] (Z2) a pharmaceutically acceptable carrier, diluent or excipient.
[0106] In another preferred embodiment, the pharmaceutical composition is a liquid preparation.
[0107] In another preferred embodiment, the pharmaceutical composition is in the form of an injection.
[0108] In another preferred embodiment, the concentration of the engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.
[0109] In the eighth aspect of the present invention, there is provided a use of the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, and / or the engineered immune cell as described in the fifth aspect of the present invention for preparing a drug or preparation for preventing and / or treating cancer or tumors.
[0110] In another preferred embodiment, the tumor is a tumor that highly expresses matrix metalloproteinases.
[0111] In another preferred embodiment, the tumor includes but is not limited to the following group:
[0112] Esophageal malignancy, lung malignancy, stomach malignancy, skin malignancy, colorectal malignancy, liver malignancy, pancreatic malignancy, breast malignancy, ovarian malignancy, glioma, head and neck tumor, or a combination thereof.
[0113] In another preferred embodiment, the tumor is esophageal malignant tumor (esophageal cancer).
[0114] In another preferred embodiment, the tumor is gastric cancer.
[0115] In another preferred embodiment, the tumor is colorectal cancer.
[0116] In another preferred embodiment, the tumor is liver cancer.
[0117] In another preferred embodiment, the tumor is pancreatic cancer.
[0118] In another preferred embodiment, the tumor is melanoma.
[0119] In another preferred embodiment, the tumor is lung cancer.
[0120] In another preferred embodiment, the tumor is ovarian cancer.
[0121] In another preferred embodiment, the tumor is breast cancer.
[0122] In another preferred embodiment, the tumor is a glioma.
[0123] In another preferred embodiment, the tumor is thyroid cancer.
[0124] In another preferred embodiment, the tumor is bladder cancer, prostate cancer, testicular cancer, cervical cancer, endometrial cancer, or skin cancer.
[0125] In another preferred embodiment, the tumor includes diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, lung squamous cell carcinoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, uterine carcinosarcoma, or a combination thereof.
[0126] In the ninth aspect of the present invention, there is provided a use of the engineered immune cell as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the seventh aspect of the present invention, for preventing and / or treating cancer or tumors.
[0127] In a tenth aspect of the present invention, a method for engineering a chimeric antigen receptor (CAR) is provided, the method comprising the steps of:
[0128] (a) providing a chimeric antigen receptor to be engineered; and
[0129] (b) Introducing a TSAR regulatory element before the antigen recognition domain of the chimeric antigen receptor to be modified, thereby obtaining a conditionally activated chimeric antigen receptor with higher safety.
[0130] In the eleventh aspect of the present invention, a kit for preparing the engineered immune cells as described in the fifth aspect of the present invention is provided, the kit comprising a container, and the nucleic acid molecule as described in the second aspect of the present invention, or the vector as described in the third aspect of the present invention, located in the container.
[0131] In the twelfth aspect of the present invention, a method for treating cancer or tumors is provided, comprising administering an effective amount of the engineered immune cells as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the seventh aspect of the present invention to a subject in need of treatment.
[0132] In another preferred embodiment, the engineered immune cells or CAR immune cells contained in the pharmaceutical composition are cells derived from the subject (autologous cells).
[0133] In another preferred embodiment, the engineered immune cells or CAR immune cells contained in the pharmaceutical composition are cells derived from healthy individuals (allogeneic cells).
[0134] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0135] Figure 1 shows a schematic diagram of the TSAR.CAR molecular structure.
[0136] Figure 2 shows the anti-tumor pattern of TSAR.CAR.
[0137] FIG3 shows flow cytometric analysis of B7-H3 expression levels on the surface of malignant esophageal tumor cell lines.
[0138] FIG4 shows the expression level of B7-H3 in malignant esophageal tumor cell lines detected by Western Blot.
[0139] FIG5 shows the protein expression levels of B7-H3 in different tissues analyzed by protein database.
[0140] FIG6 shows the analysis of B7-H3 RNA expression levels in different tumor tissues using the GEPIA database.
[0141] FIG7 shows the protein expression level of B7-H3 in different tumor tissues analyzed using protein database (HPA00928 antibody).
[0142] FIG8 shows the RNA expression levels of different MMPs in 120 pairs of esophageal squamous cell carcinoma tissues.
[0143] FIG9 shows the expression of MMP1 and MMP11 in 10 esophageal squamous cell carcinoma cell lines detected by Western blot.
[0144] FIG10 shows the expression levels of KYSE150, KYSE150-hMMP1 full length, and KYSE150-hMMP1 activated length detected by Western blot.
[0145] FIG11 shows flow cytometric analysis of the binding of HSA to HSABP.
[0146] FIG12 shows flow cytometric analysis of the cleavage of B7-H3.TSAR molecules by MMP1 treatment.
[0147] Figure 13 shows the difference in the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T against KYSE150 and KYSE150 overexpressing human MMP1 analyzed by in vitro cell experiments.
[0148] Figure 14 shows an in vivo animal experiment comparing the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T.
[0149] Figure 15 shows the in vitro experimental analysis of the anti-tumor activity of B7-H3.TSAR.CAR-T against colon cancer, liver cancer, gastric cancer, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and breast cancer cell lines. DETAILED DESCRIPTION
[0150] After extensive and in-depth research and a large amount of screening, the inventors unexpectedly discovered for the first time a special molecular structure that can increase the safety of engineered immune cells (such as chimeric antigen receptor T cells, CAR-T cells) in the treatment of malignant solid tumors: TSAR.CAR (Tumour-Selectively Activating Reaction CAR). That is, a conditionally activated regulatory element (TSAR regulatory element) is inserted after the 5' signal peptide and before the antigen recognition domain of the traditional classic CAR molecular structure, which includes: human serum albumin binding peptide (HSABP) and human matrix metalloproteinase (MMP) cleavage sequence (MMPCS). The CAR and engineered immune cells of the present invention utilize the characteristics of high expression of matrix metalloproteinases in the tumor microenvironment to achieve conditional activation based on matrix metalloproteinases, thereby reducing the toxic and side effects caused by off-target effects during immunotherapy, and improving the safety of engineered immune cell products. The present invention was completed on this basis.
[0151] the term
[0152] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.
[0153] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.
[0154] The term "administering" refers to the physical introduction of the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.
[0155] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0156] "Transduction", "transfection", "transformation" or other terms used herein refer to the process of transferring exogenous polynucleotides into host cells, transcribing and translating them to produce polypeptide products, including the use of plasmid molecules to introduce exogenous polynucleotides into host cells.
[0157] "Gene expression" or "expression" refers to the process of gene transcription, translation, and post-translational modification to produce the RNA or protein product of a gene.
[0158] Conservative amino acid substitutions are known in the art. In some embodiments, potential substituting amino acids are within one or more of the following groups: glycine, alanine; and valine, isoleucine, leucine, and proline; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine, lysine, arginine, and histidine; and / or phenylalanine, tryptophan, and tyrosine; methionine, and cysteine. In addition, the present invention also provides non-conservative amino acid substitutions that allow substitution of amino acids from different groups.
[0159] It should be understood that for any method described herein comprising more than one step, the order of the steps is not necessarily limited to the order described in the examples.
[0160] Conventional strategies for off-target effects
[0161] (1) Based on the difference in the amount of surface antigen expression between normal tissues and organs and malignant tumor cells, single-chain antibodies with different affinities for the target antigen are selected. Compared with normal tissues and organs, malignant tumor cells that express relatively high levels of target antigens can be killed by CAR-T cells expressing low-affinity scFv, thus forming a situation where only tumor cells with high target antigen density can provide sufficient interaction to activate CAR-T cells. Studies have shown that CAR-T cells with low affinity for CD19 molecules can not only effectively kill tumor cells, but also have stronger proliferation ability and low side effects. However, there are still great challenges in finding and identifying highly effective CAR low-affinity single-chain antibodies, and some studies have found that in malignant solid tumors, recombinant CAR-T cells expressing low-affinity single-chain antibodies have significantly lower anti-tumor activity than CAR-T cells expressing high-affinity single-chain antibodies.
[0162] (2) Introducing "logic gating" CAR molecules that recognize two or more antigens or lack specific antigens at the same time to optimize CAR's recognition of tumor cells. For example, the synNotch system first recognizes the first target antigen through a synthetic Notch receptor, and after activation, it can induce the expression of CAR molecules targeting the second target antigen. This dual-receptor CAR molecule can activate CAR-T cells only when it recognizes two target antigens on the cell surface. Some researchers have also found that by connecting CD3ζ and the costimulatory domain to two receptors respectively, such as one receptor with a CD3ζ activation domain and the other receptor with a costimulatory domain, only when both receptors bind to the corresponding target antigens can the entire CAR-T cell be activated and the killing function be performed. Recently, scientists have developed an inhibitory CAR molecule that connects the receptor that recognizes non-malignant tumor cells with the co-inhibitory domain to ensure that the activated CAR-T only kills tumor cells. However, this sequential activation method of "logic gating" will delay the time from CAR-T cells being infused into the body to taking effect, and the cytokines produced by the reaction are also uncontrollable.
[0163] The CAR and engineered immune cells of the present invention utilize the high expression of matrix metalloproteinases in the tumor microenvironment to achieve conditional activation based on metalloproteinases, thereby reducing toxic and side effects caused by off-target effects during immunotherapy and improving the safety of engineered immune cell products.
[0164] TSAR regulatory elements
[0165] As described above, the conditionally activated CAR molecule of the present invention contains a TSAR (tumor-selectively activating reaction) regulatory element. Typically, the TSAR regulatory element of the present invention has a nucleotide sequence as shown in SEQ ID NO: 1 and an amino acid sequence as shown in SEQ ID NO: 2.
[0166] The TSAR regulatory element consists of two parts: a serum albumin binding peptide and a matrix metalloproteinase cleavage sequence. Typically, the serum albumin binding peptide of the present invention is a human serum albumin binding peptide (HSABP); and the matrix metalloproteinase cleavage sequence (MMPCS) of the present invention is a human matrix metalloproteinase cleavage sequence.
[0167] The serum albumin binding peptide can bind to serum albumin (e.g., human serum albumin (HSA)), interfering with the binding of the single-chain antibody of the CAR molecule to the tumor cell surface antigen through steric hindrance, thereby placing genetically engineered cells such as CAR-T cells in a low / inactivated state. The serum albumin binding peptide of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 3 and an amino acid sequence as shown in SEQ ID NO: 4.
[0168] The matrix metalloproteinase cleavage sequence can be specifically cleaved by matrix metalloproteinases (MMPs), thereby relieving the steric hindrance effect mediated by HSABP and activating genetically engineered cells such as CAR-T cells. The matrix metalloproteinase cleavage sequence of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 5 and an amino acid sequence as shown in SEQ ID NO: 6.
[0169] Matrix metalloproteinases (MMPs) and matrix metalloproteinase cleavage sequences (MMPCS)
[0170] The tumor microenvironment (TME) is the internal environment in which tumor cells thrive and is a key factor contributing to the poor efficacy of CAR-T cell therapy for malignant solid tumors. The TME primarily consists of tumor cells, their surrounding immune cells, inflammatory cells, nearby interstitial tissue, blood vessels, and various cytokines, chemokines, and metalloproteinases (MMPs).
[0171] MMPs are a family of zinc- and calcium-dependent proteases that degrade the extracellular matrix and basement membrane, promoting tumor cell invasion and metastasis. Studies have found that MMPs are widely present in the tumor microenvironment of lung, breast, ovarian, cervical, liver, rectal, and bladder cancers, and their elevated expression is closely associated with poor patient prognosis. Esophageal malignant tumor tissues highly express MMP1, MMP3, MMP10, MMP12, and MMP13. High expression of MMP1 not only promotes tumor cell proliferation but is also directly associated with poor neoadjuvant chemotherapy responses. Patients with malignant esophageal cancer who have high MMP1 expression have a poor prognosis.
[0172] The matrix metalloproteinase cleavage sequence (MMPCS) is a site specifically recognized and cleaved by matrix metalloproteinases, which can relieve the steric hindrance mediated by HSABP and activate genetically engineered cells such as CAR-T cells. The matrix metalloproteinase cleavage sequence of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 5 and an amino acid sequence as shown in SEQ ID NO: 6.
[0173] CAR of the present invention (TSAR.CAR)
[0174] Chimeric antigen receptor (CAR) is composed of an extracellular antigen recognition region, a transmembrane region, and an intracellular co-stimulatory signaling region.
[0175] The design of CARs has evolved through the following process: First-generation CARs contain only a single intracellular signaling component, CD3ζ or FcγRI. Because they only have a single activation domain, they can only induce transient T cell proliferation and minimal cytokine secretion, but cannot provide long-term T cell proliferation signals or sustained in vivo anti-tumor effects, resulting in limited clinical efficacy. Second-generation CARs incorporate a co-stimulatory molecule, such as CD28, 4-1BB, OX40, or ICOS, into the existing structure. This significantly improves the function of first-generation CARs, further enhancing the persistence of CAR-T cells and their ability to kill tumor cells. New immune co-stimulatory molecules, such as CD27 and CD134, are added in tandem to the second-generation CARs, resulting in the development of third- and fourth-generation CARs.
[0176] The extracellular segment of CAR can recognize a specific antigen, and then transduce the signal through the intracellular domain, causing cell activation and proliferation, cytolytic toxicity and secretion of cytokines, thereby eliminating the target cells. First, the patient's autologous cells (or allogeneic donors) are isolated, activated and genetically modified to produce CAR immune cells, and then injected into the same patient. This method has a very low probability of developing graft-versus-host disease, and the antigen is recognized by the immune cells in a non-MHC restricted manner.
[0177] CAR-immune cell therapy has achieved a very high clinical response rate in the treatment of hematological malignancies, a high response rate that has not been achieved by any previous treatment method, and has triggered a wave of clinical research around the world.
[0178] Specifically, the chimeric antigen receptor of the present invention includes an extracellular domain, a transmembrane domain, and an intracellular domain.
[0179] The extracellular domain includes a target-specific binding element. The extracellular domain can be an scFv of an antibody based on antigen-antibody specific binding, or a natural sequence or a derivative thereof based on ligand-receptor specific binding.
[0180] The intracellular domain includes a costimulatory signaling region and a zeta chain portion. The costimulatory signaling region refers to a portion of the intracellular domain that includes costimulatory molecules. Costimulatory molecules are cell surface molecules required for lymphocytes to effectively respond to antigens, rather than antigen receptors or their ligands.
[0181] Between the extracellular domain and the transmembrane domain of CAR, or between the cytoplasmic domain and the transmembrane domain of CAR, a linker can be incorporated. As used herein, the term "linker" generally refers to any oligopeptide or polypeptide that acts to connect the transmembrane domain to the extracellular domain or cytoplasmic domain of a polypeptide chain. The linker may include 0-300 amino acids, preferably 2 to 100 amino acids and most preferably 3 to 50 amino acids.
[0182] The CAR of the present invention, when expressed in T cells, can perform antigen recognition based on antigen binding specificity. When it binds to its associated antigen, it affects tumor cells, causing them to not grow, be caused to die or be affected in other ways, and causing the patient's tumor load to shrink or be eliminated. The antigen binding domain is preferably fused with one or more intracellular domains from a costimulatory molecule and a ζ chain.
[0183] Typically, the CAR of the present invention has the structure shown in Formula I: SP-TSAR-Binder-H-TM-C-CD3ζ (I)
[0184] Wherein, each is as defined above.
[0185] It should be understood that the CAR of the present invention can be applied to a variety of tumor antigens and a variety of tumor types. When different Binders are selected, the CAR of the present invention can correspondingly target the tumor antigens and tumor cells that the Binder specifically binds to.
[0186] Taking esophageal malignancy and B7-H3 target as an example (ie, when the Binder is a B7-H3 single-chain antibody (B7-H3scFv)), the CAR of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 7 and an amino acid sequence as shown in SEQ ID NO: 8.
[0187] In non-tumor areas, HSABP in the TSAR regulatory element binds to the highly abundant HSA in the body, masking the binding of the B7-H3 scFv to the antigen through steric hindrance. This leaves the CAR-T in a low / inactive state, resulting in weak or no killing function, effectively avoiding off-target effects. However, when the TSAR.CAR-T molecule enters tumor tissue, the abundant matrix metalloproteinases (such as MMP1) in the malignant tumor tissue recognize the MMPCS in the TSAR regulatory element, removing the HSABP and its bound HSA from the front end of the B7-H3 scFv. This relieves the HSABP-mediated steric hindrance and enables the B7-H3 scFv to bind efficiently to the target antigen on the tumor cell surface, transforming it into an activated CAR-T cell and exerting its specific tumor cell-killing function. Thus, based on the design of the TSAR regulatory element, conditional activation mediated by matrix metalloproteinases is achieved, improving the safety of CAR products.
[0188] Engineered immune cells of the present invention
[0189] The chimeric antigen receptor immune cells of the present invention can be T cells, NK cells, NKT cells, or macrophages.
[0190] CAR-T cells have the following advantages over other T-cell-based treatments: (1) The action of CAR-T cells is not restricted by MHC; (2) Since many tumor cells express the same tumor markers, once the CAR gene construction for a certain tumor marker is completed, it can be widely used; (3) CAR can use both tumor protein markers and glycolipid non-protein markers, expanding the target range of tumor markers; (4) The use of the patient's own cells reduces the risk of rejection; (5) CAR-T cells have immune memory function and can survive in the body for a long time.
[0191] Natural killer (NK) cells are a major type of immune effector cell that protects the body from viral infection and tumor cell invasion through non-antigen-specific pathways. Engineered (genetically modified) NK cells may acquire new functions, including the ability to specifically recognize tumor antigens and possess enhanced anti-tumor cytotoxicity.
[0192] Compared with autologous CAR-T cells, CAR-NK cells have the following advantages: (1) they directly kill tumor cells by releasing perforin and granzymes, but have no killing effect on normal cells in the body; (2) they release very small amounts of cytokines, thereby reducing the risk of cytokine storms; (3) they are extremely easy to expand in vitro and develop into "ready-made" products. Other than that, it is similar to CAR-T cell therapy.
[0193] carrier
[0194] The nucleic acid sequence encoding the desired molecule can be obtained using recombinant methods known in the art, such as, for example, by screening libraries from cells expressing the gene, by obtaining the gene from a vector known to include the gene, or by directly isolating from cells and tissues containing the gene using standard techniques. Alternatively, the gene of interest can be produced synthetically.
[0195] The present invention also provides vectors comprising the nucleic acid molecules of the present invention. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they allow for long-term, stable integration of transgenes and their proliferation in daughter cells. Lentiviral vectors have advantages over vectors derived from oncogenic retroviruses, such as murine leukemia viruses, because they can transduce non-proliferating cells, such as hepatocytes. They also have the advantage of low immunogenicity.
[0196] In brief summary, the expression cassette or nucleic acid sequence of the present invention is generally operably linked to a promoter and incorporated into an expression vector. Such vectors are suitable for replication and integration into eukaryotic cells. Typical cloning vectors contain transcriptional and translational terminators, initiation sequences, and promoters that can be used to regulate expression of the desired nucleic acid sequence.
[0197] The expression constructs of the present invention can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Methods of gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entireties. In another embodiment, the present invention provides gene therapy vectors.
[0198] The nucleic acid can be cloned into many types of vectors. For example, the nucleic acid can be cloned into such vectors, which include but are not limited to plasmids, phagemids, phage derivatives, animal viruses and cosmids. Specific vectors of interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.
[0199] Further, expression vector can be provided to cell in the form of viral vector.Viral vector technology is well known in the art and is described in, for example, Sambrook et al. (2001, Molecular Cloning:A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. The virus that can be used as a vector includes but is not limited to retrovirus, adenovirus, adeno-associated virus, herpes virus and slow virus. Generally, suitable vectors are included in at least one organism and work in the origin of replication, promoter sequence, convenient restriction enzyme site and one or more selectable markers (for example, WO01 / 96584; WO01 / 29058; and U.S. Patent number 6,326,193).
[0200] Many virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to the subject's cells in vivo or in vitro. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In one embodiment, a lentiviral vector is used.
[0201] Additional promoter elements, such as enhancers, can regulate the frequency of transcription initiation. Typically, these are located in the 30-110 bp region upstream of the start site, although recently it has been shown that many promoters also contain functional elements downstream of the start site. The spacing between promoter elements is often flexible so that when an element is inverted or moved relative to another, promoter function is maintained. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased by 50 bp before activity begins to decline. Depending on the promoter, it has been shown that individual elements can work together or independently to initiate transcription.
[0202] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto for high-level expression. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on expression of a polynucleotide sequence operably linked to the inducible promoter when such expression is desired, or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, the metallothionein promoter, the glucocorticoid promoter, the progesterone promoter, and the tetracycline promoter.
[0203] In order to evaluate the expression of the CAR polypeptide or its portion, the expression vector introduced into the cell may also include any one or both of a selectable marker gene or a reporter gene to facilitate identification and selection of expressing cells from a cell population that is sought to be transfected or infected by a viral vector. In other aspects, selectable markers can be carried on a single DNA segment and used for co-transfection procedures. Both selectable markers and reporter genes may be flanked by appropriate regulatory sequences to enable expression in host cells. Useful selectable markers include, for example, antibiotic resistance genes, such as neo and the like.
[0204] The reporter gene is used to identify the cells of potential transfection and to evaluate the functionality of the regulatory sequence. Generally, the reporter gene is a gene that is not present in a receptor organism or tissue or is expressed by a receptor organism or tissue, and that encodes a polypeptide whose expression is clearly indicated by some easily detectable properties such as enzymatic activity. After DNA has been introduced into the receptor cell, the expression of the reporter gene is measured at the appropriate time. Suitable reporter genes can include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase, or green fluorescent protein (e.g., Ui-Tei et al., 2000 FEBS Letters 479:79-82).
[0205] Suitable expression systems are well known and can be prepared using known techniques or obtained commercially. Typically, the construct with a minimum of five flanking regions that exhibits the highest level of reporter gene expression is identified as a promoter. Such a promoter region can be linked to a reporter gene and used to evaluate the ability of an agent to regulate promoter-driven transcription.
[0206] Methods for introducing genes into cells and expressing genes in cells are known in the art. In the context of expression vectors, the vectors can be readily introduced into host cells, such as mammalian, bacterial, yeast, or insect cells, by any method known in the art. For example, expression vectors can be transferred into host cells by physical, chemical, or biological means.
[0207] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.
[0208] Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used method for inserting genes into mammalian, for example, human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, among others. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0209] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0210] In the case of using non-viral delivery system, exemplary delivery means is liposome. Consider using lipid preparation, to introduce nucleic acid into host cell (in vitro, in vitro (ex vivo) or in vivo). On the other hand, this nucleic acid can be associated with lipid. The nucleic acid associated with lipid can be encapsulated in the aqueous interior of liposome, dispersed in the lipid bilayer of liposome, attached to liposome through the connecting molecule associated with liposome and oligonucleotide, trapped in liposome, compounded with liposome, dispersed in the solution comprising lipid, mixed with lipid, united with lipid, included in lipid as suspension, included in micelle or with micelle compound, or otherwise associated with lipid. The lipid, lipid / DNA or lipid / expression vector associated with composition are not limited to any specific structure in solution. For example, they can be present in bilayer structure, as micelle or have " collapsed (collapsed) " structure. They can also be simply dispersed in solution, may form aggregates of size or shape inhomogeneity. Lipid is a fatty substance, which can be a naturally occurring or synthetic lipid. For example, lipids include fat droplets that occur naturally in the cytoplasm as well as compounds that contain long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
[0211] In a preferred embodiment of the present invention, the vector is a lentiviral vector.
[0212] Pharmaceutical composition
[0213] The present invention provides a pharmaceutical composition comprising: a conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, a nucleic acid molecule as described in the second aspect of the present invention, a vector as described in the third aspect of the present invention, a host cell as described in the fourth aspect of the present invention, or an engineered immune cell as described in the fifth aspect of the present invention, and a pharmaceutically acceptable carrier, diluent, or excipient. In one embodiment, the pharmaceutical composition is a liquid preparation. Preferably, the pharmaceutical composition is an injection. Preferably, the concentration of the engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.
[0214] In one embodiment, the formulation may include a buffer such as neutral buffered saline, sulfate buffered saline, or the like; a carbohydrate such as glucose, mannose, sucrose, or dextran, mannitol; a protein; a polypeptide or amino acid such as glycine; an antioxidant; a chelating agent such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative. The pharmaceutical composition of the present invention is preferably formulated for intravenous administration.
[0215] Therapeutic applications
[0216] In one embodiment, the present invention comprises a type of cell therapy in which a patient's own T cells (or those of an allogeneic donor) are isolated, activated, and genetically modified to produce CAR-T cells, which are then infused back into the same patient. This approach minimizes the likelihood of a graft-versus-host reaction, as antigens are recognized by T cells in an MHC-free manner. Furthermore, a single CAR-T cell can treat all cancers expressing that antigen. Unlike antibody therapies, CAR-T cells are able to replicate in vivo, resulting in long-term persistence that can lead to sustained tumor control.
[0217] The CAR-T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or with other components such as IL-2, IL-17 or other cytokines or cell populations. Briefly, the pharmaceutical compositions of the present invention may include a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
[0218] The pharmaceutical compositions and engineered immune cells of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The quantity and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease, or can be determined by clinical trials.
[0219] When an "immunologically effective amount," "anti-tumor effective amount," "tumor-inhibitory effective amount," or "therapeutic amount" is indicated, the precise amount of the composition of the present invention to be administered can be determined by a physician, who takes into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. The pharmaceutical composition comprising the T cells described herein can be administered in an amount of 10 4 to 10 9 The dose of cells / kg body weight is preferably 10 5 to 10 7 The T cell composition can be administered at a dose of 10 cells / kg body weight (including all integer values within the range). The T cell composition can also be administered multiple times at these doses. The cells can be administered using infusion techniques known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988). The optimal dosage and treatment regimen for a particular patient can be easily determined by a person skilled in the art of medicine by monitoring the patient's signs of disease and adjusting the treatment accordingly.
[0220] Administration of the subject composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The compositions described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intraspinal, intramuscularly, by intravenous injection or intraperitoneally. In one embodiment, the T cell composition of the present invention is administered to the patient by intradermal or subcutaneous injection. In another embodiment, the T cell composition of the present invention is preferably administered by intravenous injection. The T cell composition can be injected directly into the tumor, lymph node or infection site.
[0221] In certain embodiments of the present invention, cells activated and expanded using the methods described herein or other methods known in the art for expanding T cells to therapeutic levels are administered to a patient in combination with (e.g., before, simultaneously, or after) any number of related treatment modalities, including, but not limited to, treatment with agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (also known as ARA-C), or natalizumab treatment for MS patients, or efavirenz treatment for psoriasis patients, or other treatments for PML patients. In further embodiments, the T cells of the present invention may be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and FK506, antibodies, or other immunotherapeutic agents. In further embodiments, the cell compositions of the present invention are administered to a patient in combination with (e.g., before, simultaneously, or after) bone marrow transplantation, chemotherapy agents such as fludarabine, external beam radiation therapy (XRT), or cyclophosphamide. For example, in one embodiment, a subject may undergo standard treatment with high-dose chemotherapy followed by a peripheral blood stem cell transplant. In some embodiments, the subject receives an infusion of the expanded immune cells of the invention following transplantation. In an additional embodiment, the expanded cells are administered before or after surgery.
[0222] The dosage of the above treatments administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. Dosage ratios for human administration may be implemented according to practices accepted in the art. Typically, 1×10 5 to 1×10 10 The modified T cells of the present invention are administered to the patient, for example, by intravenous infusion.
[0223] Main advantages of the present invention
[0224] 1. The conditionally activated CAR and engineered immune cells of the present invention can effectively avoid off-target effects, thereby reducing toxic side effects and improving safety.
[0225] 2. When the conditionally activated CAR and engineered immune cells of the present invention exert their killing function, the extracellular conditionally activated regulatory elements have been cut off. Therefore, the presence of the conditionally activated regulatory elements of the present invention will not affect the killing function of the engineered immune cells themselves.
[0226] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0227] Sequence information
[0228] Example 1 Construction of recombinant B7-H3.TSAR.CAR molecules and preparation of T cells expressing the CAR molecules
[0229] In this example, taking esophageal malignancy and B7-H3 as an example, a recombinant B7-H3.TSAR.CAR molecule (as shown in FIG1 ) was constructed and T cells expressing the CAR molecule were prepared in the following steps:
[0230] ① Artificially synthesize a CAR molecule containing a fusion gene of the TSAR regulatory element and the B7-H3 single-chain antibody (SEQ ID NO: 7);
[0231] ②Insert the artificially synthesized fusion gene into the lentiviral plasmid;
[0232] ③Use 293T cells to package and produce lentivirus to prepare lentivirus carrying B7-H3.TSAR.CAR molecules;
[0233] ④ Isolate mononuclear cells from peripheral blood using Ficoll, and further enrich T cells using CD3 magnetic beads;
[0234] ⑤Use the lentivirus prepared in step ③ to infect human peripheral blood T cells to prepare recombinant B7-H3.TSAR.CAR-T cells, and amplify B7-H3.TSAR.CAR-T in vitro for subsequent in vitro and in vivo experiments.
[0235] As shown in Figure 2, a schematic diagram of the anti-tumor effect of TSAR.CAR-T cells of the present invention is shown: Since the human body contains a large amount of human serum albumin, when TSAR.CAR-T enters the non-tumor area of the human body, HSABP can immediately bind to HSA, causing the extracellular structure of the CAR-T cell to change. Due to the steric hindrance effect, the scFv cannot smoothly bind to the B7-H3 protein, and the B7-H3.TSAR.CAR-T is in an inactive state. When B7-H3.TSAR.CAR-T enters the tumor area, MMP1, which is abundantly expressed in solid tumor tissue, can cut B7-H3.TSAR.CAR-T at the MMPCS site, eliminating the steric hindrance effect, and B7-H3.TSAR.CAR-T becomes a classic activated B7-H3.CAR-T. The scFv binds to the tumor antigen binding region and the target antigen B7-H3 on the surface of the tumor cell, exerting its tumor-killing function.
[0236] Example 2 Detection of B7-H3 expression levels on the surface of esophageal malignant tumor cell lines using flow cytometry
[0237] In this example, taking esophageal malignant tumors and B7-H3 as an example, flow cytometry was used to detect the expression level of B7-H3 on the surface of esophageal malignant tumor cell lines. The specific steps are as follows:
[0238] ① Use EDTA to digest the KYSE30 / 70 / 140 / 150 / 180 / 270 / 410 / 450 / 510 / 520 cell lines in the logarithmic growth phase;
[0239] ② Wash 3 times with PBS;
[0240] ③ Resuspend in 50 μl PBS, add PE-labeled B7-H3 (PE) antibody, and incubate at 4°C in the dark for 45 min;
[0241] ④ Wash 3 times with PBS;
[0242] ⑤ Resuspend in 200 μL PBS and detect the PE expression level by flow cytometry.
[0243] As shown in Figure 3 , B7-H3 was positively expressed in all esophageal squamous cell carcinoma cells.
[0244] Example 3 Detection of B7-H3 protein levels in esophageal malignant tumor cell lines using Western blot
[0245] In this example, taking esophageal malignant tumors and B7-H3 as an example, Western blot was used to detect the B7-H3 protein level in esophageal malignant tumor cell lines. The specific steps are as follows:
[0246] ①Extract total protein from KYSE30 / 70 / 140 / 150 / 180 / 270 / 410 / 450 / 510 / 520 cell lines and quantify;
[0247] ② Take 10 μg of protein for sample loading;
[0248] ③Western blot (electrophoresis, transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of B7-H3 protein content.
[0249] As shown in Figure 4 , Western blot results showed that B7-H3 was positively expressed in all esophageal squamous cell carcinoma cells.
[0250] Example 4 Bioinformatics Analysis of B7-H3 Protein Expression Levels in Different Tissues
[0251] In this example, the Proteinatlas database (https: / / www.proteinatlas.org) was used to analyze the protein expression of B7-H3 in normal tissues.
[0252] As shown in Figure 5 , B7-H3 is positively expressed in a variety of tissues, particularly the choroid plexus, adrenal gland, salivary gland, lung, stomach, gallbladder, pancreas, urinary bladder, prostate, endometrium, and placenta.
[0253] Example 5 Bioinformatics Analysis of B7-H3 RNA Expression Levels in Different Tumor Tissues
[0254] In this example, the GEPIA database (http: / / gepia2.cancer-pku.cn) was used to analyze the RNA expression of B7-H3 in different tumor tissues.
[0255] As shown in Figure 6, B7-H3 levels in COAD (colon cancer), DLBC (diffuse large B-cell lymphoma), ESCA (esophageal cancer), GBM (diffuse large B-cell lymphoma), HNSC (head and neck squamous cell carcinoma), KIRC (clear cell renal carcinoma), KIRP (renal papillary cell carcinoma), LGG (low-grade glioma of the brain), LUSC (lung squamous cell carcinoma), PAAD (pancreatic cancer), SKCM (cutaneous melanoma), STAD (gastric adenocarcinoma), TCGT (testicular germ cell tumor), THYM (thymoma), and UCS (uterine carcinosarcoma) were significantly higher than those in adjacent cancer tissues.
[0256] Example 6 Bioinformatics Analysis of B7-H3 RNA Expression Levels in Different Tumor Tissues
[0257] In this example, the Proteinatlas database (https: / / www.proteinatlas.org) was used to analyze the protein expression of B7-H3 in different tumor tissues, and the antibody number was HPA00928.
[0258] As shown in Figure 7, CD276 protein is expressed in glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck tumors, gastric cancer, liver cancer, pancreatic cancer, bladder cancer, prostate cancer, testicular cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma, and skin cancer.
[0259] Example 7 RNA Sequencing Analysis of MMPs RNA Expression in 120 Pairs of Esophageal Squamous Cell Carcinoma Tissues
[0260] This example involves the expression of MMPs family members in esophageal squamous cell carcinoma tissue, and the specific steps are as follows:
[0261] ① Collect 120 pairs of esophageal squamous cell carcinoma specimens (including tumor tissue and corresponding adjacent tissue);
[0262] ② RNA high-throughput sequencing was used to analyze the RNA expression profiles of 120 pairs (240) of clinical specimens;
[0263] ③The RNA expression of 17 MMPs (MMP1, MMP2, MMP3, MMP7, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23B, MMP25 and MMP28) was analyzed by bioinformatics, and a related heat map was drawn.
[0264] As shown in Figure 8 , except for MMP28, the expressions of the other 16 MMPs members in tumors were higher than those in adjacent tissues.
[0265] Example 8 Expression of MMP1 and MMP11 in ten esophageal squamous cell carcinoma cell lines
[0266] This example involves verifying the expression of MMP1 protein in tumor cells, and the specific steps are as follows:
[0267] ① Extract and quantify proteins from 10 tumor cell lines;
[0268] ②Western blot (electrophoresis, transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of MMP1 protein content.
[0269] As shown in Figure 9, ESCC cells express not only the full-length MMP1 (MMP1 OL) protein, but also the active (22 / 25 kD, MMP1 AL) and inactive (27 kD) segments. MMP11 protein expression levels vary across ESCC cell lines, with relatively high levels in KYSE70, KYSE150, and KYSE510 cells and relatively low levels in KYSE410 and KYSE520 cells.
[0270] Example 9 Construction of MMP1 overexpressing cells and protein expression verification
[0271] This example involves the construction of MMP1 overexpressing cells and protein expression verification, and the specific steps are as follows:
[0272] ① The full-length and active segments of MMP1 (98-276AA) were obtained by PCR, and a recombinant lentiviral plasmid expressing MMP1 was constructed;
[0273] ②Use 293T cells to package and produce lentivirus containing the full-length and active segments of MMP1;
[0274] ③ KYSE150 cells were infected with lentivirus containing the full-length MMP1 and the active segment of MMP1 to construct a KYSE150 cell line overexpressing the full-length MMP1 (KYSE150-hMMP1) and the active segment of MMP1 (KYSE150-hMMP1 activated length);
[0275] ④ Extract total protein from KYSE150 / KYSE150-hMMP1 / KYSE150-hMMP1 activated length cell lines and quantify;
[0276] ⑤Western blot (electrophoresis, transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of MMP1 protein content.
[0277] As shown in Figure 10, Western blot results showed that compared with non-transduced KYSE150 cells, the expression level of MMP1 in KYSE150 cells overexpressing full-length MMP1 and overexpressing active fragment of MMP1 was significantly increased.
[0278] Example 10 Flow cytometric analysis of B7-H3.TSAR.CAR-T cells to effectively bind to HSA via HSABP
[0279] This example involves flow cytometry analysis of the effective binding of B7-H3.TSAR.CAR-T to HSA via HSABP. The specific steps are as follows:
[0280] ① Take 1 mg of human serum albumin and label it with FITC-NHS activated ester. After terminating the reaction, use dialysis to remove excess fluorescent dye.
[0281] ②T, B7-H3.CAR-T, and B7-H3.TSAR.CAR-T were starved for 24 h (cultured in X-VIVO medium without human serum albumin and IL-2 at 37°C for 24 h);
[0282] ③ The starved cells were incubated with HSA-FITC at room temperature or 4°C for 10 min, 20 min, and 30 min, respectively;
[0283] ④After washing with PBS three times, the FITC positive rate was analyzed by flow cytometry.
[0284] As shown in Figure 11, the FITC positivity rate of B7-H3.TSAR.CAR-T was significantly higher than that of control T cells and B7-H3.CAR-T cells without regulatory elements, indicating that the recombinant B7-H3.TSAR.CAR can effectively bind to HSA.
[0285] Example 11 Flow cytometric analysis of whether T cells expressing B7-H3.TSAR.CAR molecules can be activated by MMP1
[0286] This example involves flow cytometry analysis of whether T cells expressing B7-H3.TSAR.CAR molecules can be activated by MMP1. The specific steps are as follows:
[0287] ①Construct HSABP-MMPCS-scFv plasmid;
[0288] ② Induced expression of HSABP-MMPCS-scFv protein in vitro;
[0289] ③ Label the HSABP-MMPCS-scFv protein with FITC-NHS activated ester to obtain HSABP-MMPCS-scFv-FITC protein;
[0290] ④EDTA digestion of KYSE150 cells;
[0291] ⑤ After deactivation, some cells were incubated with HSABP-MMPCS-scFv-FITC at 37°C for 1 hour, and another part of the cells were incubated with activated MMP1 protein (activated by APMA at 37°C for 2 hours) and HSABP-MMPCS-scFv-FITC at 37°C for 1 hour;
[0292] ⑥ Detection of FITC expression by flow cytometry.
[0293] As shown in FIG12 , the cell group containing activated MMP1 protein was able to better bind to the fluorescently labeled HSABP-MMPCS-scFv recombinant protein, demonstrating that MMP1 cleavage can relieve the blocking effect of HSA on the single-chain antibody.
[0294] Example 12 In vitro analysis of the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T against KYSE150 and KYSE150-hMMP1 activated length
[0295] The killing ability of CAR-T cells was detected by cell LDH release experiment for 24 hours. The inventors found that B7-H3.CAR-T cells had a significantly higher killing effect on KYSE150 cells with low MMP1 expression than B7-H3.TSAR.CAR-T. When co-incubated with KYSE150-hMMP1 overexpressing MMP1, B7-H3.TSAR.CAR-T and B7-H3.CAR-T had the same killing effect (as shown in Figure 13), proving that MMP1 can activate B7-H3.TSAR.CAR-T cells and exert anti-tumor activity.
[0296] These results demonstrate that B7-H3.TSAR.CAR-T's ability to kill tumor cells can be conditionally activated through MMP1, improving safety: in cells with low MMP1 expression, B7-H3.TSAR.CAR-T is in a low activation state; whereas in cells with high MMP1 expression, B7-H3.TSAR.CAR-T is effectively activated. Furthermore, the results demonstrate that TSAR regulatory elements do not affect the tumor cell-killing effect of B7-H3.TSAR.CAR-T.
[0297] Example 13 In vivo animal experiment comparing the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T
[0298] This example involves an in vivo animal experiment to compare the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T. The specific steps are as follows:
[0299] ① Take 4-6 week old B-NDG mice and subcutaneously inoculate 4×10 KYSE70 cells 6 / Only.
[0300] ② Wait until the subcutaneous tumor volume increases to 100 mm 3 At the same time, the animals were divided into PBS group, T group, B7-H3.CAR-T group, and B7-H3.TSAR.CAR-T group (6 animals in each group), and the group treatment was performed twice;
[0301] ③The body weight and tumor volume of B-NDG mice were measured twice a week, and the changes in tumor volume among different treatment groups were compared.
[0302] As shown in Figure 14, the results showed that both B7-H3.TSAR.CAR-T and B7-H3.CAR-T effectively inhibited tumor growth in the MMP1-overexpressing cell line KYSE-70, with no significant difference in anti-tumor activity between the two. Therefore, the TSAR regulatory element does not affect the killing effect of B7-H3.TSAR.CAR-T on tumor cells.
[0303] Example 14 In vitro analysis of the anti-tumor activity of B7-H3.TSAR.CAR-T against various tumor cells
[0304] In this example, the anti-tumor activity of B7-H3.TSAR.CAR T cells was determined by luciferase assay, and the specific steps were as follows:
[0305] ①Resuscitate and inoculate colorectal cancer Colo205 cells, liver cancer HuH7 cells, gastric cancer SGC7901 cells, pancreatic cancer Panc1 cells, lung cancer NCI-H460 cells, melanoma A375 cells, and ovarian cancer SKOV3 cells into 12-well plates;
[0306] ② Add 50 μL of lentivirus expressing GFP and Luciferase (titer is 3*10 7 ), 5 μg Polybrene infection enhancer, fresh cell culture medium was replaced 12 h after virus infection, and culture was continued for 72 h;
[0307] ③ 72 hours after infection, add blasticidin at a final concentration of 10 μg / mL for resistance screening for 3-5 days;
[0308] 5,000-10,000 cells were inoculated with control T (ConT) and B7-H3.TSAR.CAR-T cells at different effector-target ratios in an opaque sterile culture plate and incubated in a 37°C incubator for 24 hours;
[0309] ④ Add 20 μL (1 μg / μL) of luciferase substrate;
[0310] ⑤ Analyze the luciferase activity of the remaining cells using a Promega GloMax assay;
[0311] ⑥Statistical analysis of the anti-tumor activity of T cells.
[0312] As shown in Figure 15, the anti-tumor activity of B7-H3.TSAR.CAR-T against colorectal cancer Colo205 cells, liver cancer HuH7 cells, gastric cancer SGC7901 cells, pancreatic cancer Panc1 cells, lung cancer NCI-H460 cells, melanoma A375 cells, and ovarian cancer SKOV3 cells was significantly higher than that of the control cells, and with the increase of the effector-target ratio, the anti-tumor activity of B7-H3.TSAR.CAR-T gradually increased.
[0313] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A conditionally activated chimeric antigen receptor (CAR), characterized in that: The conditionally activated chimeric antigen receptor comprises: (i) an extracellular domain comprising a TSAR regulatory element and an antigen recognition domain; (ii) a transmembrane domain linked to the extracellular domain; and (iii) an intracellular domain linked to the transmembrane domain; in: The TSAR regulatory elements include: serum albumin binding peptide and matrix metalloproteinase cleavage sequence; The antigen recognition domain targets tumor antigens.
2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the conditionally activated chimeric antigen receptor according to claim 1.
3. A carrier, characterized in that The vector contains the nucleic acid molecule according to claim 2.
4. A host cell, characterized in that The host cell contains the vector according to claim 3, or has the exogenous nucleic acid molecule according to claim 2 integrated into its chromosome, or expresses the conditionally activated chimeric antigen receptor according to claim 1.
5. An engineered immune cell, characterized in that: The engineered immune cell contains the vector as described in claim 3, or an exogenous nucleic acid molecule as described in claim 2 is integrated into its chromosome, or it expresses the conditionally activated chimeric antigen receptor as described in claim 1, and the engineered immune cell is a T cell, NK cell, NKT cell, or macrophage.
6. A method for preparing the engineered immune cell according to claim 5, characterized in that: The method comprises the following steps: transducing the nucleic acid molecule according to claim 2 or the vector according to claim 3 into immune cells, thereby obtaining the engineered immune cells.
7. A pharmaceutical composition, characterized in that The pharmaceutical composition contains: (Z1) the conditionally activated chimeric antigen receptor of claim 1, the nucleic acid molecule of claim 2, the vector of claim 3, the host cell of claim 4, the engineered immune cell of claim 5, or a combination thereof; and (Z2) a pharmaceutically acceptable carrier, diluent or excipient.
8. A use of the conditionally activated chimeric antigen receptor according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the host cell according to claim 4, and / or the engineered immune cell according to claim 5, characterized in that: Used for preparing medicines or preparations for preventing and / or treating cancer or tumors.
9. A method for modifying a chimeric antigen receptor (CAR), characterized in that: The method comprises the steps of: (a) providing a chimeric antigen receptor to be modified; and (b) introducing a TSAR regulatory element in front of the antigen recognition domain of the chimeric antigen receptor to be modified, This will result in a safer conditionally activated chimeric antigen receptor.
10. A kit for preparing the engineered immune cell according to claim 5, the kit comprising a container, and the nucleic acid molecule according to claim 2 or the vector according to claim 3 located in the container.
Citation Information
Patent Citations
Protease activation CD45 gated car
CN116761816A
Masking chimeric antigen receptor t cells for tumor-specific activation
US20180148508A1
Conditionally active receptors
US20220054544A1
Compositions and methods comprising protease-activated therapeutic agents
US20220281936A1
Multicistronic chimeric protein expression systems
WO2023205614A2
